Mecasermin Rinfabate
drugOn this page
Also known as Mecasermin rinfabate recombinantMecasermina rinfabatoMecasermine rinfabateRHIGF-I/RHIGFBP-3
Summary
Mecasermin Rinfabate (CHEMBL1201717) is an approved protein (ATC H01AC05); indicated across 4 conditions including retinopathy of prematurity and myotonic dystrophy.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: H01AC05
- Indications: 4 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201717 |
| Name | Mecasermin Rinfabate |
| Type | Protein |
| Max phase | 4 |
| ATC | H01AC05 |
Also known as: Mecasermin rinfabate, Mecasermin rinfabate recombinant, Mecasermina rinfabato, Mecasermine rinfabate, RHIGF-I/RHIGFBP-3, MECASERMIN RINFABATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| retinopathy of prematurity | 2 | MONDO:0006952 | EFO:1001158 |
| myotonic dystrophy | 2 | MONDO:0016107 | Orphanet:273 |
| Laron syndrome | 2 | MONDO:0009877 | MONDO:0009877 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00368173 | PHASE2/PHASE3 | COMPLETED | IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome |
| NCT00577577 | PHASE2 | COMPLETED | Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 |
| NCT01096784 | PHASE2 | COMPLETED | IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.